Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults

Reuters

28 May

Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults

NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2538491466"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538491466\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538491466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538491466","market":"nz","top_or_hot":-1,"title":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-28 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPIX","symbol_name":"坎伯兰药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL2yzZbT:1","article_id":"2538491466","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538491466","pubTimestamp":1748376346,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor as Safe and Effective Opioid-Sparing Pain Management for Older Adults. NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc.  has announced the publication of a new clinical study assessing Caldolor  in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPIX":"坎伯兰药业","BK4557":"大麻股","BK4007":"制药"},"translate_title":"Cumberland Pharmaceuticals公布的研究证实Caldolor®可安全有效地治疗老年人阿片类药物疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPIX":0.9},"content_text":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    \n\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}